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A B S T R A C T
During the past 25 years, we came across 60 patients with corticotroph pituitary adenomas and Cushing’s disease.
Neuroradiological examination showed prominent volume loss of the brain parenchyma, unexpected for the patient’s
age. This »brain atrophy« appeared to regress after surgical removal of pituitary adenoma and normalization of cortisol
level. Observed difference between degree of »brain atrophy« in the Cushing’s disease group and in the control group was
statistically significant (p<0.001). The degree of »brain atrophy« correlated well with the duration of Cushing’s disease.
Partial reversibility of »brain atrophy« was noticed during the 2nd, 3rd and 4th year after surgery and normalization of
cortisol level. Increased cortisol level is one of the causative factors in pathogenesis of »brain atrophy«. Loss of brain vol-
ume is at least partially reversible after normalization of cortisol levels.
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Introduction
Patients with Cushing’s disease caused by ACTH-se-
creting pituitary adenoma, constitute a very complex
group of patients with peculiar clinical symptoms and
high number of potential complications associated with
surgical treatment1,2. Due to anatomical and morphologi-
cal characteristics of ACTH adenomas, especially their
small size, commonly encountered are false-negative se-
llar computed tomography (CT) scans (67%), pituitary
magnetic resonance (MR) imaging scans (48%), as well as
cases with ectopic ACTH secretion3,4. Difficulty in ob-
taining accurate location of ACTH pituitary adenoma
has been reported even after sampling of the inferior
petrosal sinus5,6. Therefore, in majority of cases our deci-
sion for surgical treatment has been based on clinical
manifestations and laboratory findings.
Analyzing the brain CT and MR scans of patients
with Cushing’s disease, we have noticed diffuse brain
volume loss disconcordant with patient’s age. Observed
»brain atrophy« was so prominent, that in some cases
with borderline clinical and laboratory findings, brain
volume loss almost became a lead diagnostic tool.
Long-term follow-up of surgically treated patients
with Cushing’s disease caused by ACTH-secreting pitu-
itary adenoma was conducted. Partial, or in some cases
complete remission of brain atrophy after normalization
of cortisol level was noticed on control postoperative CT
and MR scans. In this report, a group of 39 patients with
Cushing’s disease was examined to assess the presence
and degree of brain atrophy and its remission after sur-
gery and normalization of cortisol level.
Systemic effects of hypercortisolism are well known
and described7. However, the data on structural alter-
ations of human brain in Cushing’s disease are limited
and not emphasized in the literature as a detectable
manifestation of this disease. In 1971 Momose et al. de-
scribed the presence of diffuse cerebral atrophy in 74% of
patients with Cushing’s disease using pneumoencephalo-
graphy8. Starkman et al. found decreased hippocampal
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formation volume in 27% of 12 patients with Cushing’s
disease on magnetic resonance imaging9. Heinz et al. de-
scribed a 9-year-old boy with Cushing’s disease and ap-
parent severe cerebral atrophy which recuperated almost
completely after successful disease treatment10. Stark-
man et al. reported a mean 3.2% ± 2.5% increase in
hippocampal formation and caudate nucleus volumes fol-
lowing treatment in 22 patients with Cushing’s disease11.
Decrease of cortisol levels, usually 16 months after sur-
gery, is correlated with the volume increase in those two
brain structures, with the increase of hippocampal vol-
ume being twice that of caudate nucleus. As evidence of
the well-known dexamethasone antiedematous effect, the
amount of water in the gray and white matter of the
brain, including the hippocampus, increases with de-
creased cortisol levels12,13. Although changes in brain vol-
ume may be caused by variations in the amount of water
in the brain, the fact that cortisol level normalization has
stronger effect on hippocampus than on caudate nucleus
indicates that an additional mechanism is likely to play a
role9,11. Hippocampus in adults of different species has
the ability to generate new granular neuronal cells and
in humans the production of new neurons has been al-
ready proven14. Increase in hippocampal volume was
shown to be directly associated with amelioration of cog-
nitive functions11,15.
Patients and Methods
Patients
Since 1980 we have operated on more than 1300 sellar
tumors, including 60 patients with ACTH-secreting pitu-
itary adenoma and clinical signs of Cushing’s disease.
This retrospective study included 39 patients with
Cushing’s disease caused by an ACTH-secreting pitu-
itary adenoma who had successful surgical treatment
and whose medical data were available. The selection cri-
teria for successful surgery and normalization of Cush-
ing’s disease were: 1) regression of clinical symptoms,
and 2) postoperative normal plasma ACTH and cortisol
levels and/or normal urinary free cortisol concentration.
Analyzed group included 10 male and 29 female patients,
ageing from 8–56 years old, median age 33.2 ± 13.9 years.
There were 5 children (0–14 yrs), 5 adolescents (15–19
yrs) and 29 adults (³20 yrs).
Out of the remaining 21 patients, who were not ana-
lyzed, 11 patients had an incomplete tumor removal, 3
patients died, 2 patients had incomplete medical records
and 5 patients did not answer the call for investigation.
The control group consisted of 39 patients: 5 with
growth hormone (GH)-secreting microadenoma, 5 with
prolactin (PRL)-secreting microadenoma, 10 with hor-
monally inactive pituitary adenoma and 19 patients in
who brain CT and/or MR scans were performed for con-
ditions not related to intracranial masses, metabolic dis-
orders, cerebrovascular disease or other conditions in-
ducing brain atrophy. All patients within this group had
normal ACTH and cortisol levels. They were 10–57 years
old, with median age 40.1 ± 13.8 years. There were 12
men and 27 woman; 5 children, 2 adolescents, and 32
adults. The control group was necessary in order to dem-
onstrate the difference in »brain atrophy« degree be-
tween patients with and without Cushing’s disease.
Surgery
All patients with ACTH-secreting pituitary adenomas
and with other pituitary adenomas from the control
group were surgically treated using standard transsphe-
noidal approach. In all 39 patients an ACTH-secreting
adenoma was diagnosed using pathohistological and
immunohistochemical analysis.
Radiological examination
16 out of 39 patients had sellar CT using DRH Sie-
mens with coronal 2mm thick sections, before and after
administration of 60 mL contrasting agent (380 mg Jod/
mL). The remaining 23 patients were evaluated using a
1.0 T Siemens-Harmony MR scanner. Magnetic reso-
nance imaging included sagittal and coronal T1-weighted
sequences before and after administration of paramag-
netic contrast agent (0.1 mL/kg), coronal postcontrast
dynamic T1-weighted image, as well as axial and coronal
T2-weighted images, all with 3 mm slice thickness. Post-
operative neuroradiological examinations were perfor-
med using same diagnostic devices as the preoperative
scans, under same technical conditions so the scans
taken before and after surgery could be compared. Neuro-
radiological evaluation was done for clinical purposes.
Therefore, at our disposal we had CT or MR scan pic-
tures with neuroradiological description, without elec-
tronic version of the scans. Therefore, we used judgment
received from two neuroradiologists who were blinded to
all patient data and who independently reviewed all im-
aging materials. Any disagreements were solved by con-
sensus on an additional review. Using this procedure, we
were able to avoid and test for subjectivity in assessing
the degree of »brain atrophy«.
Statistical analysis
The degree of »brain atrophy« was measured and de-
termined according to the scale proposed by Momose in
19718 and modified by Simmons in 200016, and classified
as follows: 0 – no atrophy; 1 – minimal atrophy; 2 – mod-
erate atrophy; 3 – severe atrophy. Data obtained from
neuroradiologists were compared using Cohen’s Kappa
test. Data used in further analysis were obtained from a
neuroradiologist who, in evaluating the brain atrophy in
each case, used a higher degree. Patients were divided in
subgroups according to the duration of the disease: one
year or less, 2–3 years, 4–5 years, 6 and more years. Re-
gression of the degree of brain volume loss was analyzed
during 4 years after surgery.
Results are sorted in Table 1 and 2. Patients with
Cushing’s disease and patients from the control group
were compared using c2 test. The degree of brain atrophy
in different time period was analyzed with Stuart-Max-
well test17,18.
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Results
In our series there was significant discordance in
evaluation of »brain atrophy« degree between two neuro-
radiologists (control group: k= 0.267; Cushing’s disease:
k= 0.125), but only for one degree, in four grade scale, in
all cases.
Observed difference in the degree of »brain atrophy«
in patients with Cushing’s disease before operation and
control group was statistically significant (c2= 23,673; p
< 0.001, Table 1).
There was statistically significant difference in distri-
bution of patients according to preoperative assessment
of »brain atrophy« degree and disease duration (c2=
8,344; p = 0.004, Table 2 and Figure 1).
The »brain atrophy« degree before and one, two,
three and four years after surgery was analyzed. No sta-
tistically significant difference was found in brain atro-
phy degree before and one year after surgery (p=0.172)
but there was statistically significant difference in »brain
atrophy« degree two, three and four years after surgery
(p=0.003, 0.002 and 0.001 respectively, Figure 2).
Discussion
In our series, according to the c2 test, the »brain atro-
phy« degree was statistically significantly higher in pa-
tients with Cushing’s disease when comparing with the
control group (p<0.001), despite the fact that control
group was, in average, slightly older. This result con-
firmed our empiric observation and justified further in-
vestigation. Similar results were presented by other au-
thors who used comparable methodology9,16. The »brain
atrophy« degree increased with preoperative duration of
Cushing’s disease. So, when Cushing’s disease lasted one
year or less, only minimal atrophy was observed and in
case of prolonged Cushing’s disease, proportion of »brain
atrophy« degree changed in advantage of medium and se-
vere atrophy. Statistical significance was noticed when
comparing patients with disease duration of more or less
than six years (Figure 3 and 4).
Despite the effort to precisely detect the beginning of
the Cushing’s disease it is highly possible that disease
lasted longer before it was diagnosed. Other authors, es-
pecially Simmons et al. detected correlation between du-
ration of hypercortisolism and degree of brain atrophy16.
Analyzing the whole specimen, one year following the
surgery and normalization of blood cortisol level, degree
of brain atrophy showed improvement on control neuro-
radiological imaging in 5 patients and while the remain-
ing 34 patients findings were unchanged. After surgery
»brain atrophy« regressed, so already two years later
@. Gnjidi} et al.: Cerebral Atrophy in Cushing’s Disease, Coll. Antropol. 32 (2008) 4: 1165–1170
1167
TABLE 2
DISTRIBUTION OF PATIENTS ACCORDING PREOPERATIVE
ASSESSMENT OF BRAIN ATROPHY DEGREE AND DISEASE
DURATION
Disease
duration
(years)
Brain atrophy degree
Minimal Medium + severe
 6 19 4

2=8,344
p=0.004>6 6 10
TABLE 1
DISTRIBUTION OF PATIENTS ACCORDING TO PREOPERATIVE
ASSESSMENT OF BRAIN ATROPHY DEGREE IN CONTROL
GROUP AND IN GROUP WITH CUSHING’S DISEASE
c2= 23,673; p < 0.001
Group
Cushing’s disease
n (%)
CONTROL
n (%)
No atrophy 0 (0%) 16 (41.0%)
Minimal atrophy 25 (64.1%) 20 (51.3%)
Medium or severe atrophy* 14 (35.9%) 3 (7.7%)
Total 39 (100%) 39 (100%)
* In only two patients with Cushing’s disease severe brain atro-
phy was observed
< 1 god. 2–3 god. 4–6 god. > 6 god.
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Fig. 1. Proportion of patients according to the duration of Cush-
ing’s disease: minimal atrophy (open bars), medium atrophy
(dotted bars), severe atrophy (striped bars).
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Fig. 2. The brain atrophy degree before, one, two, three and four
years after surgery: no atrophy (open bars), minimal atrophy (doted
bars), medium atrophy (wave bars), severe atrophy (striped bars).
there was significant improvement in »brain atrophy«.
Three and four years after surgery results were even
better, clearly indicating positive effect of surgery on de-
gree of »brain atrophy«.
Bourdeau et al. described a group of 38 patients with
Cushing’s syndrome and found a subjective loss of brain
volume in 86% of patients with Cushing’s disease and
100% of patients with adrenal Cushing’s syndrome. Par-
tial reversibility of anatomical modifications of brain vol-
ume was observed in most patients 40 months after
cortisol level normalization what correlates with our re-
sults where four years after cortisol level normalization
there was no further change in brain atrophy degree.
We have used the term »brain atrophy« because it was
often used by the neuroradiologists. Quotation-marks
were used due to the doubt of accuracy of this term.
Bourdeau favors the term »loss of brain volume« over the
term »brain atrophy« due to partial reversibility and lack
of evidence for brain atrophy in patients with Cushing’s
disease. Partial reversibility of cerebral atrophy which
correlates with hypercortisolism clearly indicates that
the loss of brain volume is not only a consequence of
neuronal cell death19.
Bourdeau states that the loss of brain volume is a dif-
fuse process, not limited to hippocampal formation, often
seen in patients with Cushing’s syndrome either pitu-
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a) b)
Fig. 3. Patient with Cushing’s disease, operated 2 years after the onset of symptoms. a) Coronal T1-weighted image one year after sur-
gery shows mild (Grade 1) brain volume loss, with prominent lateral ventricles and Sylvian fissures. b) Corresponding coronal
T1-weighted image two years after surgery demonstrates interval improvement without significant (Grade 0) brain volume loss.
a) b)
Fig. 4. Patient with Cushing’s disease, operated 6 years after the onset of symptoms. a) Midsagittal T1-weighted image one year after
surgery shows severe (Grade 3) volume loss, especially in the cerebellum with very thin vermian folia. b) Corresponding sagittal
T1-weighted image three years after surgery reveals significant interval improvement with only mild (Grade 1) volume loss.
itary or adrenal etiology. Brain volume loss is finally par-
tially reversible after cortisol level normalization indicat-
ing that ACTH is not responsible for structural changes
in the brain. Brain volume loss is not associated with
other pituitary lesions. These investigations correlate
with the results of Starkman et al.9,11,15. Bordeau also
stated that further studies are necessary in order to es-
tablish when complete recovery of brain volume loss is
possible and how this recovery correlates with neuropsy-
chological improvement20. According to the latest litera-
ture review there are four theories on mechanisms lead-
ing to glucocorticoid-induced brain atrophy and hippo-
campal changes7. These theories are: decreased utiliza-
tion of glucose as glucocorticoids affect cellular glucose
metabolism; increased actions of excitatory amino acid
neurotransmitters such as glutamate; presynaptic reduc-
tion of neurotrophic factors leading to inhibition of long-
-term potentiation, and finally suppressed neurogenesis
in the subgranular layer of the dentate gyrus leading to
granular neurons and hippocampal volume loss7.
The study of McEwen et al., on stress and cognitive
function emphasized that occupation of mineralocorti-
coid receptors by physiological concentrations of cortisol
in hippocampal cell cultures is essential for maintaining
neuronal cell survival and function21–28. On the other
hand, occupation of glucocorticoid receptors by supra-
physiological values of cortisol initially leads to decreased
cell excitability and reversible atrophy of apical dendrites
of CA3 pyramidal neurons in culture.
Brain is a plastic structure with an ability to reverse
its structural changes, which is confirmed by studies on
effect of prolonged stress and prolonged exposure to excess
glucocorticoids that suggest reversibility of changes in
the neuronal cell structure, especially in hippocampus24.
Partial recovery in brain volume loss in both studies
suggests that some aspects of Cushing’s syndrome can-
not be completely reversible. Only detailed follow-up of
these patients in future will determine reversibility of
brain atrophy after surgical treatment.
Merke et al. analyzed changes in brain structure and
cognitive function in children 8–16 years of age with en-
dogenous Cushing’s disease. They noticed that the effect
of supraphysiological levels of glucocorticoids on children
differs from that on the adults. Adults more commonly
exhibit brain volume loss, memory disturbances, and de-
pression with partial or complete remission following
normalization of cortisol levels29.
However, in our series there were 5 children (8–14
years) and 5 adolescents where the degree of brain atro-
phy was not smaller than in adult patients. In postopera-
tive follow-up during four years there was no statistically
significant difference in regression of brain atrophy de-
gree between these two subgroups – young patients and
adult patients.
The limitation of our study is its retrospective nature
which did not allow us to conduct a randomized trial.
Cushing’s disease is a good model for investigation of
influence of high cortisol level on human brain. Patho-
genesis of brain volume loss in chronic hypercortisolism
is multifactorial. Changes in brain volume loss in the
past treated as irreversible damage today seem to be re-
versible. Partial recovery in brain volume loss after pro-
longed hypercortisolism suggests that some aspects of
neurological damage are not completely reversible.
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REVERZIBILNA »ATROFIJA MOZGA« U PACIJENATA SA CUSHINGOVOM BOLESTI
S A @ E T A K
Unazad 25 godina lije~ili smo 60 pacijenata sa kortikotropnim adenomima hipofize i Cushingovom bolesti. Neuro-
radiolo{ko snimanje pokazalo je zna~ajan gubitak volumena mo`danog parenhima, neo~etkivan za pacijentovu dob.
Izgleda da ta »mo`dana atrofija« regredira nakon kirur{kog odstranjenja adenoma hipofize i normalizacije razine korti-
zola. Razlika u utvr|enoj razini »atrofije mozga« u Cushingovoj bolesti i u kontrolnoj skupini je statisti~ki zna~ajna
(p<0,001). Stupanj »mo`dane atrofije« korelira dobro sa trajanjem Cushingove bolesti. Djelomi~no povla~enje »atrofije
mozga« primije}eno je dvije, tri i ~etiri godine nakon kirur{kog lije~enja i normalizacije razine kortizola. Povi{ena razi-
na kortizola je jedan od uzro~nih faktora u patogenezi »mo`dane atrofije«. Smanjenje volumena mozga je djelomi~no
reverzibilno nakon normalizacije razine kortizola.
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